British consumer healthcare group Haleon on Thursday said 2025 revenue and profit growth would be weighted to the second half ...

UK's Haleon reported annual profit in line with market expectations on Thursday, as the Sensodyne toothpaste and Advil ...

Haleon's dividend grew 10% and is well-covered by FCF, but the 1.6% yield is less attractive compared to peers. See why I ...

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains ...

Haleon projects a gradual revenue and profit ... The company, which makes Sensodyne toothpaste, ENO antacids and Centrum multivitamins, projected organic revenue would grow between 4 per cent ...

Sensodyne-maker Haleon’s annual profits rose in line with expectations last year as it got a boost in demand for its oral ...

HALEON PLC (LON:HLN) shares slid 3% in London on Thursday after the Sensodyne toothpaste maker said its revenue growth for 2025 would be weighted toward the second half of the year.

Haleon, which focuses on over-the-counter medicines, oral health, and vitamins, minerals and supplements, generated £1.9bn in ...

KARACHI: Haleon Pakistan Limited, a consumer healthcare company, has renewed its collaboration with Smile Train, ...

Learn more about whether Haleon plc or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.